Tekla Capital Management’s Exact Sciences EXAS Stock Holding History

Tekla Capital Management’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-225,282	Closed	-$21.5M	–	174
2021 Q3	$21.5M	Buy	225,282 +25,628	+13%	+$2.71M	0.69%	42
2021 Q2	$24.8M	Buy	199,654 +32,352	+19%	+$3.86M	0.81%	32
2021 Q1	$22M	Buy	167,302 +103,800	+163%	+$14.2M	0.76%	35
2020 Q4	$8.41M	Buy	63,502 +48,352	+319%	+$5.85M	0.3%	94
2020 Q3	$1.54M	Sell	15,150 -28,865	-66%	-$2.49M	0.06%	166
2020 Q2	$3.83M	Buy	44,015 +20,882	+90%	+$1.67M	0.15%	116
2020 Q1	$1.34M	Buy	+23,133	New	+$1.88M	0.06%	157

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Tekla Capital Management's EXAS Position: Q4 2021 in Review

Tekla Capital Management sold out of Exact Sciences (EXAS) in Q4 2021, closing a stake of 225,282 shares — an estimated $21.5M sold.

Tekla Capital Management first reported a position in EXAS in Q1 2020 and held it in 7 quarters. The position peaked at $24.8M in Q2 2021. 596 funds tracked by Wall St. Rank hold EXAS as of Q4 2021.

Tekla Capital Management reported no remaining Exact Sciences position as of Q4 2021 after selling out during the quarter.
Tekla Capital Management sold 225,282 Exact Sciences shares in Q4 2021, an estimated $21.5M.
Tekla Capital Management first reported a position in Exact Sciences in Q1 2020 and held it in 7 quarters.
Tekla Capital Management's Exact Sciences position peaked at $24.8M in Q2 2021.
596 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2021.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.